Evidence map›Paper›PMID 35460010›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Two Diseases-One Preclinical Treatment Targeting Glycogen Synthesis.

Matthew S Gentry, Kia H Markussen, Katherine J Donohue

Abstract readComment
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Matthew S GentryDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, USA. matthew.gentry@uky.edu.ORCID 0000-0001-5253-9049
Kia H MarkussenDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, USA.
Katherine J DonohueDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, USA.

Funding

Suppressing glycogen storage with small molecule inhibitors as a therapeutic approach to Lafora DiseaseP01NS097197 · NINDS · UNIVERSITY OF KENTUCKY · PI GAO, TIANYAN · 2016 to 2021
$9.0M
Brain Glycogen-Metabolism,Mechanisms, and Therapeutic PotentialR35NS116824 · NINDS · UNIVERSITY OF KENTUCKY · PI Matthew S. Gentry · 2020 to 2026
$8.2M
NINDS NIH HHS P01 NS097197NINDS NIH HHS R35 NS116824
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GlycogenMuscle, SkeletalGlycogenAAV9Adult polyglucosan body diseaseGlycogenGlycogen storage diseaseLafora diseaseNeurodegeneration

Identifiers

PMID35460010
PMCPMC9294113

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.